Issue: February 2024
Fact checked byHeather Biele

Read more

December 07, 2023
2 min read
Save

GLP-1 receptor agonists may protect against CRC in patients with type 2 diabetes

Issue: February 2024
Fact checked byHeather Biele
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Key takeaways:

  • Glucagon-like peptide 1 receptor agonists were associated with a decreased risk for CRC compared with insulin and metformin.
  • GLP-1RAs also were associated with a lower CRC risk in overweight and obese patients.

Glucagon-like peptide 1 receptor agonists were associated with a reduced risk for colorectal cancer among patients with type 2 diabetes, regardless of weight status, compared with other antidiabetics, according to research.

“To our knowledge, this is the first indication this popular weight-loss and antidiabetic class of drugs reduces incidence of CRC, relative to other antidiabetic agents,” Rong Xu, PhD, co-lead researcher and professor of biomedical informatics at Case Western Reserve University School of Medicine, said in a related university press release.

Nathan Berger, MD

To compare the effects of glucagon-like peptide 1 receptor agonists (GLP-1RAs) and non-GLP-1RAs on the risk for CRC, Xu and colleagues conducted a nationwide, retrospective cohort study using deidentified electronic health records obtained via the TriNetX platform.

They included 1,221,218 drug-naive patients with type 2 diabetes from 59 health care organizations nationwide who were prescribed antidiabetic medications from 2005 to 2019. Patients were propensity score matched for demographics, socioeconomic and lifestyle factors, medical history and procedures such as colonoscopy.

The non-GLP-1RAs used for comparison were insulin, metformin, alpha-glucosidase inhibitors, dipeptidyl-peptidase 4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, sulfonylureas and thiazolidinediones.

The primary outcome was the first diagnosis of CRC within 15 years of the first prescription date.

According to results published in JAMA Oncology, GLP-1RAs were associated with a decreased risk for CRC compared with insulin (HR = 0.56; 95% CI, 0.44-0.72), metformin (HR = 0.75; 95% CI, 0.58-0.97), SGLT2 inhibitors (HR = 0.77; 95% CI, 0.62-0.97), sulfonylureas (HR = 0.82; 95% CI, 0.68-0.98) and thiazolidinediones (HR = 0.82; 95% CI, 0.69-0.97).

Researchers also reported GLP-1RAs were associated with a “lower but not statistically significant” risk for CRC compared with alpha-glucosidase (HR = 0.59; 95% CI, 0.31-1.13) or DPP-4 inhibitors (HR = 0.93; 95% CI, 0.78-1.1).

Further, GLP-1RAs were associated with a decreased risk for CRC among those classified as obese or overweight compared with insulin (HR = 0.5; 95% CI, 0.33-0.75), metformin (HR = 0.58; 95% CI, 0.38-0.89) or other antidiabetics.

“Our results clearly demonstrate that GLP-1RAs are significantly more effective than popular antidiabetic drugs, such as metformin or insulin, at preventing the development of CRC,” Nathan Berger, MD, co-lead researcher and Hanna-Payne Professor of Experimental Medicine at Case Western Reserve School of Medicine, said in the release. “The research is critically important for reducing incidence of CRC in patients with diabetes, with or without overweight and obesity.”

Reference: